Paper
0
Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML
Authors
Courtney DiNardo,Eytan Stein
Stéphane Botton,Gail Roboz,Jessica Altman,Alice Mims,Ronan Swords,Robert Collins,Gabriel Mannis,Daniel Pollyea,Will Donnellan,Amir Fathi,Arnaud Pigneux,Harry Erba,Gabrielle Prince,Anthony Stein,Geoffrey Uy,James Foran,Elie Traer,Robert Stuart,Martha Arellano,James Slack,Mikkael Sekeres,Christophe Willekens,Sung Choe,Hongfang Wang,Vickie Zhang,Katharine Yen,Stephanie Kapsalis,Hua Yang,David Dai,Bin Fan,Meredith Goldwasser,Hua Liu,Sam Agresta,Bin Wu,Eyal Attar,Martin Tallman,Richard Stone
+37 authors
,Hagop KantarjianPublished
Jun 2, 2018
Show more
Save
Tip0
TipSave
Abstract
Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in 6 to 10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.